Evidence map›Paper›PMID 41160230›Full record

ArticleJournal of neurology2025

Correction: Longitudinal evaluation of serum neurofilament light levels in normal healthy volunteers: defining a threshold of concern.

Thomas A Lanz, Klemens Ruprecht, Christopher J Somps, Jens C Göpfert, Tony Kam-Thong, Fetene Tekle, Kelly A Fader, Viviana A Carcamo Yañez, Volker Meyer, Sabine Friedrich and 5 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Thomas A LanzPfizer Inc., Drug Safety R&D, Groton, CT, USA. Thomas.a.lanz@pfizer.com.ORCID http://orcid.org/0000-0003-2483-3122
Klemens RuprechtDepartment of Neurology, Heidelberg University Hospital, Heidelberg, Germany.
Christopher J SompsPfizer Inc., Drug Safety R&D, Groton, CT, USA.
Jens C GöpfertNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Tony Kam-ThongRoche Pharma Research and Early Development, Data and Analytics, Roche Innovation Center Basel, Basel, Switzerland.
Fetene TekleJohnson & Johnson, Innovative Medicine R&D, Beerse, Belgium.
Kelly A FaderPfizer Inc., Translational Clinical Sciences, Groton, CT, USA.
Viviana A Carcamo YañezNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Volker MeyerABX-CRO Advanced Pharmaceutical Services, Dresden, Germany.
Sabine FriedrichABX-CRO Advanced Pharmaceutical Services, Dresden, Germany.
Katerina VlasakovaMerck & Co., Inc., Nonclinical Drug Safety, Rahway, NJ, USA.
Carolin OttoDepartment of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
Sara A PacigaPfizer Inc., Translational Clinical Sciences, Groton, CT, USA.
Sophia L SamodelovDept of Clinical Pharmacology & Toxicology, University Hospital Zürich, Zurich, Switzerland.
Shashi K RamaiahPfizer Inc., Drug Safety R&D, Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41160230
PMCPMC12572098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.